Core Insights - Novonesis has been recognized as a 2026 Great Employer to Work for in North Carolina, marking its first time receiving this honor based on employee feedback and evaluation of workplace practices [1][2][6] Company Recognition - Novonesis ranked 6th among the Great Employers to Work for in North Carolina, reflecting its commitment to creating a workplace where employees can thrive and contribute to meaningful work [2][6] Workplace Culture - The company emphasizes a culture centered around respect, inclusion, and continuous learning, aiming to empower employees to bring their authentic selves to work and collaborate across disciplines [3][5] - Novonesis promotes a purpose-driven career path, focusing on the idea of 'The biological choice' to inspire employees to make a difference in various industries [3][5] Operations and Workforce - Novonesis operates major facilities in Franklinton, Morrisville, and Durham, employing over 700 individuals, including scientists, engineers, and manufacturing specialists [2][4] - The company is involved in over 30 industries, driving innovation to help customers produce sustainably and reduce environmental impact [4] Community Engagement - Novonesis has been a part of North Carolina for over 40 years, investing in workforce development, advanced manufacturing, and STEM education partnerships to strengthen the state's biotechnology and biomanufacturing sectors [5]

Core Insights - Novonesis reported strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% for the year 2025, with expectations for continued growth in 2026 [1][2][3] Financial Performance - The company achieved broad-based organic sales growth of 7% in 2025, with a Q4 growth of 4%. The exit from certain countries negatively impacted growth by approximately 1 percentage point [2] - The Food & Health segment saw an 8% organic sales growth, while the Planetary Health segment achieved 6% organic sales growth, with notable double-digit growth in Energy [2] - Emerging Markets grew 9% organically, while Developed Markets grew 6% [3] - The adjusted EBITDA margin increased to 37.1%, up by 100 basis points from the previous year, despite currency headwinds [3] - Adjusted net profit rose by 17% [3] Cash Flow and Dividends - Free cash flow before acquisitions was EUR 770.4 million, representing 19% of sales [4] - A proposed dividend of DKK 4.25 per share was announced, with a pay-out ratio of 58.4% of adjusted net profit for 2025 [4] Product Innovation and Sustainability - The company launched 33 new products in 2025, contributing to 25% of total sales from innovations launched over the last five years [4] - Novonesis achieved all six environmental and social targets for 2025 and is on track for future commitments [4] 2026 Outlook - The company anticipates organic sales growth between 5-7% for 2026, with a good start to the year expected [5] - The outlook includes a potential negative impact of approximately 1 percentage point from exiting certain countries, but also includes positive contributions from pricing and sales synergies [5] - The adjusted EBITDA margin is expected to be between 37-38%, with anticipated margin expansion despite currency headwinds [5]

Core Insights - The company reported a strong organic sales growth of 9% in the first half of the year, with an upward revision of the full-year guidance to a range of 6-8% [1][3] - Profitability remains solid despite currency headwinds, with an adjusted EBITDA margin of 37.4%, up by 210 basis points compared to the previous quarter [3] - The company achieved cost synergies at a 100% run rate, indicating improved operational efficiency [3] Sales Performance - Organic sales growth in the Food & Health segment reached 10%, while the Planetary Health segment saw a growth of 9% [3] - Emerging markets experienced a robust organic sales growth of 12%, compared to 8% in developed markets [3] Financial Metrics - Adjusted net profit increased by 23%, reflecting strong financial performance [3] - The company maintained a net interest-bearing debt to EBITDA ratio of 2.1x, following the acquisition of dsm-firmenich's part of the Feed Enzyme Alliance [3] Shareholder Returns - A share buyback program worth EUR 100 million was completed on June 27, enhancing shareholder value [3] - An interim dividend of 2.25 DKK (EUR 0.30) was approved for the first half of 2025 [3] Future Outlook - The company has narrowed its 2025 organic sales growth outlook to 6-8%, with a range of 7-9% excluding exits from certain countries [3] - Long-term financial targets for 2030 have been announced, indicating a strategic focus on growth and investment in unique biosolutions [1][3]

Core Insights - Novonesis has announced its 'GROW' strategy, aiming for long-term growth with a focus on core business acceleration and significant reinvestments until 2030 [1][2] - The company targets an organic sales CAGR of 6-9%, an adjusted EBITDA margin of approximately 39%, and an adjusted ROIC excluding goodwill of around 16% by 2030 [1][6] Business Strategy - The strategy emphasizes strong performance in biosolutions, leveraging deep customer understanding, innovation, and scalability to meet increasing demand driven by population growth, energy needs, and climate risks [1][2] - Novonesis plans to explore new growth areas, including Biopharma Processing Aids, Future Fuels and Chemicals, and Specialized Nutrition Proteins, targeting applications with significant untapped potential [2] Financial Projections - Organic sales growth is expected to be primarily driven by volume and annual price contributions of 1-2%, with emerging markets anticipated to grow faster than developed markets [6] - The adjusted EBITDA margin is projected to be around 39% by 2030, with a significant investment in innovation and market capabilities to support both short- and long-term growth [6] - The adjusted ROIC excluding goodwill is expected to rise from a pro forma 8.3% in 2024 to approximately 16% by 2030 [6] Capital Expenditure and Financial Management - Capital expenditures (Capex) will be elevated at the beginning of the strategy period to support sustained high growth, gradually decreasing to high-single-digit percentages of sales towards the end of the period [6] - The company targets a net debt/EBITDA ratio of around 1.5x and maintains a clear capital allocation model with an expected dividend payout ratio of 40-60% of adjusted net profit [6]